NCT04880876 A Study Evaluating Oral Eluxadoline Administered to Pediatric Participants With Irritable Bowel Syndrome With Diarrhea (IBS-D) Status ENROLLING_BY_INVITATION Phase PHASE3
NCT04872790 Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia Status ACTIVE_NOT_RECRUITING Phase PHASE1
NCT04862286 Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT04853368 Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsules of Galicaftor/Navocaftor/ABBV-119 or Galicaftor/Navocaftor/ABBV-576 Combination Therapies in Adult Participants With Cystic Fibrosis Status TERMINATED Phase PHASE2
NCT04846959 Study to Evaluate Pregnancy Outcomes in Risankizumab Exposed Pregnancies Relative to Those Non-risankizumab Exposed Pregnancies in Women With FDA Approved Indications Status RECRUITING Phase N/A
NCT04846244 A Study of the Change in Early and Sustained Pain Control in Axial Spondylarthritis in Adult Participants Receiving Upadacitinib Status COMPLETED Phase N/A
NCT04837482 A Study to Assess the Impact and Adverse Events of Topical Eyedrops of AGN-190584 on Night-driving Performance in Participants, 40 to 55 Years of Age Status COMPLETED Phase PHASE3
NCT04832724 RGX-314 Gene Therapy Pharmacodynamic Study for Neovascular Age-related Macular Degeneration (nAMD) Status COMPLETED Phase PHASE2
NCT04827368 Volatile Organic Compounds (VOCs) in Active Inflammatory Bowel Disease Status ACTIVE_NOT_RECRUITING Phase N/A
NCT04826523 Study of Oral Venetoclax Tablets to Evaluate Adverse Events and Change in Disease Activity in Participants Above 19 Years of Age With Acute Myeloid Leukemia (AML) Status COMPLETED Phase N/A
NCT04818515 Study To Assess Adverse Events and Drug to Drug Interaction of Oral Tablet Atogepant and Ubrogepant in Adult Participants With a History of Migraine Status COMPLETED Phase PHASE1
NCT04818385 Study to Assess the Change in Disease State When Subcutaneous Risankizumab Injection is Given to Adult Participants With Psoriasis in Taiwan Status COMPLETED Phase N/A
NCT04813263 Study of Oral Venetoclax Tablets to Evaluate Adverse Events and Change in Disease Activity in Participants of Any Age With Acute Myeloid Leukemia Status COMPLETED Phase N/A
NCT04810598 Study to Assess Adverse Events and the Movement of Oral Venetoclax Tablet Through the Body of Female Participants Aged 18-75 Years With Impaired Renal Function Status COMPLETED Phase PHASE1
NCT04807972 Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 is Administered in Combination With IV Modified FOLFIRINOX (mFFX) With or Without IV Budigalimab Compared to mFFX in Adult Participants With Untreated Pancreatic Cancer Metastasis Status TERMINATED Phase PHASE1
NCT04804254 Study to Evaluate Adverse Events, Change in Disease Activity, Movement of Oral ABBV-623 and ABBV-992 Tablets in the Body of Adult Participants With B-cell Cancers Status TERMINATED Phase PHASE1
NCT04801797 Venetoclax + Azacitidine vs. Induction Chemotherapy in AML Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT04799990 Study to Assess Adverse Events When Subcutaneous Risankizumab Injection is Given to Adult Participants With Psoriasis in Real World Setting Status WITHDRAWN Phase N/A
NCT04799353 Study to Evaluate the Safety and How the Body Handles a Single Dose of Subcutaneous (SC) and Intravenous (IV) Budigalimab in Adult Participants Living With Human Immunodeficiency Virus (HIV) Status COMPLETED Phase PHASE1